ADCT
NYSE · Biotechnology
Adc Therapeutics Sa
$3.94
-0.11 (-2.72%)
Financial Highlights (FY 2026)
Revenue
92.30M
Net Income
-205,668,432
Gross Margin
91.6%
Profit Margin
-222.8%
Rev Growth
+27.9%
D/E Ratio
3.72
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 91.6% | 91.6% | 56.3% | 56.3% |
| Operating Margin | -184.4% | -166.0% | 17.5% | 15.8% |
| Profit Margin | -222.8% | -211.7% | 14.9% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 92.30M | 72.20M | 66.42M | 54.81M |
| Gross Profit | 84.55M | 66.13M | 37.41M | 30.87M |
| Operating Income | -170,240,700 | -119,840,930 | 11.64M | 8.67M |
| Net Income | -205,668,432 | -144,780,280 | 9.87M | 6.47M |
| Gross Margin | 91.6% | 91.6% | 56.3% | 56.3% |
| Operating Margin | -184.4% | -166.0% | 17.5% | 15.8% |
| Profit Margin | -222.8% | -211.7% | 14.9% | 11.8% |
| Rev Growth | +27.9% | +27.9% | +3.3% | +12.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 204.50M | 204.50M | 206.57M | 213.23M |
| Total Equity | 55.02M | 55.02M | 282.56M | 265.87M |
| D/E Ratio | 3.72 | 3.72 | 0.73 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -152,548,603 | -113,352,501 | 12.50M | 10.42M |
| Free Cash Flow | — | — | 3.90M | 4.50M |